{"id":"W2587327379","doi":"10.1093/annonc/mdx008","title":"Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Merck","keywords":"Medicine; Pembrolizumab; Oncology; Lung cancer; Internal medicine; First line therapy; Phases of clinical research; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002047728,0.0002192512,0.000650619,0.00008369912,0.0002407926,0.00001555215,0.000226577,0.0001735387,0.0001346264],"category_scores_gemma":[0.00006399638,0.0001639169,0.0002286733,0.00005903531,0.0002076631,0.0001092437,0.00002892369,0.0001274359,0.000001913818],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008923395,"about_ca_system_score_gemma":0.0006512694,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004473372,"about_ca_topic_score_gemma":0.0002052308,"domain_scores_codex":[0.9987158,0.0000349053,0.0003876475,0.0003292472,0.0001702734,0.0003621854],"domain_scores_gemma":[0.9980817,0.0001697764,0.0006582346,0.0004527246,0.0005253944,0.0001121931],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7637408,0.003499622,0.00283953,0.00009883346,0.0005228788,0.00001628234,0.0006090194,0.000003932171,0.002008303,0.000005996013,0.002581109,0.2240737],"study_design_scores_gemma":[0.697059,0.1462776,0.02678852,0.0003128636,0.0002300565,0.000006382758,0.00006947049,0.000106989,0.04190341,0.00004666037,0.0868698,0.0003292826],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9880193,0.001199841,0.00009148757,0.003895402,0.0005266237,0.003156301,0.0001880675,0.00001587909,0.002907122],"genre_scores_gemma":[0.9921461,0.003965616,0.0003187882,0.001952309,0.0003238045,0.0005061991,0.00008259842,0.00003676363,0.0006678667],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2237444,"threshold_uncertainty_score":0.6684339,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04446429030586001,"score_gpt":0.4057339487908878,"score_spread":0.3612696584850277,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}